At a glance
ClinicalIndex Comparison RecordN/ACompleted· 386 enrolled
Drug / intervention
CT-152 - Digital Therapeutic +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Controlled Trial to Evaluate the Effectiveness of a Digital Therapeutic (CT-152) as Adjunctive Therapy in Adult Subjects Diagnosed With Major Depressive Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Feb 25, 2021·Updated Oct 16, 2024
In Brief
A clinical study evaluating CT-152 - Digital Therapeutic and Sham for Major Depressive Disorder. Completed, enrolled 386 participants across 1 site.
Detailed Summary
This study compares the effectiveness of 2 digital therapeutics in adult participants diagnosed with major depressive disorder (MDD) who are on antidepressant therapy (ADT) monotherapy for the treatment of depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
CollaboratorsClick Therapeutics, Inc.
Timeline
N/ACompletedFinished
20222023202420252026
First PostedFeb 2021
Enrollment StartFeb 2021
Primary CompletionOct 2022
TodayJul 2026
First PostedFeb 25, 2021
Enrollment StartFeb 25, 2021
Primary CompletionOct 26, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.4 years ago
Interventions
CT-152 - Digital Therapeuticdevice
CT-152 mobile app was used by the participants as per the schedule specified in the respective arm.
Shamdevice
Sham mobile app was used by the participants as per the schedule specified in the respective arm.